ClinicalTrials.gg
RecruitingNCT06014138ISO-DRIVEUpdated Jun 4, 2026

Volatile Sedation for Patients With the Acute Respiratory Distress Syndrome

A Phase 2/3 interventional study of Propofol and Isoflurane in Acute Respiratory Distress Syndrome, Mechanical Ventilation Complication and Sedation Complication, sponsored by Guy's and St Thomas' NHS Foundation Trust. Recruiting at 1 site in United Kingdom. Open to participants aged 17 Years and older. Per ClinicalTrials.gov, last updated 2026-06-04.

Sponsored by Guy's and St Thomas' NHS Foundation Trust · Phase 2/3, Interventional, and Basic science

How we know

From the registry’s dates

  • Started Nov 2023; still recruiting 3 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
20
Allocation
Non-randomized
Ages
17 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 47 studies in Respiratory Distress Syndrome with a site in United Kingdom — 10 open to participants now, 13 under way, 3 of them phase 3. Respiratory Distress Syndrome · United Kingdom.

Planned enrollment
29th of 31
20 · median 90
Started
2023
with 2 others
Phase 2/3
Only one
of the 47
Primary completion
2027-07
later than 5 of 12 live
Registered
39th of 47
by date
Lead sponsor
5 of 47
Guy's and St Thomas' NHS Foundation Trust

Among the 47 studies in Respiratory Distress Syndrome with a site in United Kingdom, this one is the 29th largest by planned enrollment of the 31 interventional ones that give a count, is one of 3 that started in 2023, is the only one in phase 2/3, reaches primary completion later than 5 of the 12 other live ones, and was the 39th registered.

Respiratory Distress Syndrome

1,389 studies on the registry are indexed under Respiratory Distress Syndrome; 281 are open to participants now.

Browse Respiratory Distress Syndrome studies →

Open to participants now

10 of the 47 studies in Respiratory Distress Syndrome with a site in United Kingdom are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 196 Respiratory Distress Syndrome studies recruiting now, 116 (59%) set no upper age limit and 50 (26%) stop at 75 or younger; 52 take children under 18; 9 take healthy volunteers.

This study: 17 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 47 studies in Respiratory Distress Syndrome with a site in United Kingdom, or all of them as a file.
02

Study summary

This study will investigate how different types of routine sedation may affect patient's breathing whilst on a ventilator in the Intensive Care Unit (ICU). There are different approaches to sedation which may have advantages and disadvantages. During the study patients will receive both intravenous and inhaled volatile sedation (similar to anaesthetic 'gases' used for general anaesthesia) and the drive to breath, breathing efforts and function of the lung will be assessed.

Read the detailed description

It is routine for patients to be sedated for their comfort and safety whilst on a ventilator in the Intensive Care Unit (ICU). Conventionally sedatives are given intravenously, however inhaled volatile sedation is becoming more popular. Inhaled sedation has recently been approved by the National Institute for Health and Clinical Excellence (NICE) in the United Kingdom (UK).

Whilst being on a ventilator can be life-saving, it can cause potential problems. It is important that the patient interacts well with the ventilator and that their own breathing efforts are well regulated. There is evidence that inhaled sedation can specifically help the lungs when patients have the Acute Respiratory Distress Syndrome (ARDS) and in particular, inhaled sedation does not appear to suppress patient's own breathing as much as conventional sedation. Greater spontaneous breathing by the patient is usually positive but needs to be carefully understood to ensure it is not excessive or damaging to the patient's already injured lungs.

This study of 20 patients is designed to carefully measure the impact of inhaled sedation on the patient's breathing and lung function, in comparison to intravenous sedation. Measurements will be taken whilst on intravenous sedation before the patient is switched to an equivalent level of inhaled sedation for six hours, when the measurements will be repeated. Finally, the patient will go back to their original intravenous sedation and the measurements taken again. This is called a 'cross-over' study and is a good way to evaluate the effect of the drug.

03

Conditions studied

  • Acute Respiratory Distress Syndrome
  • Mechanical Ventilation Complication
  • Sedation Complication
04

Who can participate

Ages eligible
17 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients admitted to the Intensive Care Unit (ICU)
  • ARDS
  • Invasive mechanical ventilation (IMV)
  • Spontaneous breathing in pressures support mode (PSV) for less than or equal to 48 hours
  • Sedated with intravenous sedation (ie. propofol and / or midazolam and fentanyl or alternate short acting opioid)
  • Anticipated to remain on IMV and PSV and with a stable sedation score for a further 24 hours without planned sedation interruption / spontaneous breathing trial or other significant change in the level of ventilator support
  • Not receiving / anticipated to receive paralysis
  • In supine position

Exclusion criteria

Exclusion Criteria:

  • Personal or family history of malignant hyperpyrexia
  • Known or suspected elevated intracranial pressure
  • High dose vasopressors (ie. Noradrenaline > 0.3mcg/kg/min or equivalent)
  • to oesophageal balloon (i.e. oesophageal / upper gastro-intestinal pathology)
  • Pregnancy
  • High dose oral sedatives (e.g. benzodiazepines) or opioids (e.g. oxycodone / oral morphine) which may affect respiratory drive
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Active comparator
    Conventional intravenous sedation

    Conventional intravenous sedation (e.g. propofol) with short acting opioid, titrated to a clinically prescribed sedation score. Period of observation will be 2 hours pre-cross over and 2 hours post cross over.

    Drug: Propofol

  • Active comparator
    Inhaled volatile sedation

    Inhaled volatile sedation (Isoflurane) delivered via the AnaConDa device for a 6 hour period (2 hours washout of intravenous sedation / wash-in of volatile to achieve stable baseline, followed by 4 hours of observations at steady state) titrated to an equivalent sedation score. During this period opioid infusion should be maintained at baseline level unless clinical indication for titration of dose.

    Drug: Isoflurane

Interventions

  • Standard care, propofol sedation - 2 hour periods of observation before and after inhaled volatile sedation

  • Inhaled volatile sedation for 6 hours - 2 hours wash in / wash out, followed by 4 hours of observations

06

What researchers measure

Primary outcomes

  1. Respiratory drive (P0.1)

    Negative pressure in the first 100milliseconds of inspiration (P0.1) - Physiological parameter

    Time frame: 8 hours

Secondary outcomes

  1. Respiratory effort (Pmus)

    End expiratory occlusion pressure (Pmus) - Physiological parameter

    Time frame: 8 hours

  2. Respiratory effort (PMI)

    Pressure Muscle Index (PMI) - Physiological parameter

    Time frame: 8 hours

  3. Respiratory effort (Oesophageal pressure swings)

    Oesophageal pressure swings - Physiological parameter

    Time frame: 8 hours

  4. Gas exchange (PaO2:FiO2 ratio)

    Ratio of arterial partial pressure of oxygen to fractional inspired concentration of oxygen (PaO2:FiO2) - Physiological parameter

    Time frame: 8 hours

  5. Gas exchange (pulmonary shunt fraction (Qs/Qt))

    Pulmonary shunt fraction (Qs/Qt) - Physiological parameter

    Time frame: 8 hours

  6. Gas exchange ( ratio of ventilatory 'dead space' to tidal volume (Vd/Vt))

    ratio of ventilatory 'dead space' to tidal volume (Vd/Vt) - Physiological parameter

    Time frame: 8 hours

  7. Gas exchange (volume of carbon dioxide breathed out (VCO2))

    volume of carbon dioxide breathed out (VCO2) - Physiological parameter

    Time frame: 8 hours

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2023 (actual). Primary completion is estimated for Jul 2027, 44 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 21, 2023
First posted
Aug 28, 2023
StartActual
Nov 1, 2023
Primary completionEst.
Jul 31, 2027
CompletionEst.
Jul 31, 2027
Last update
Jun 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06014138
Collaborators
Sedana Medical
Responsible party
Sponsor
First posted
Aug 28, 2023
Start date
Nov 1, 2023
Primary completion
Jul 31, 2027 (estimated)
Completion
Jul 31, 2027 (estimated)
Last update
Jun 4, 2026

Study contacts

Guy Glover
Contact
guy.glover@gstt.nhs.uk
00447879696250
Gill Radcliffe
Contact
gillian.radcliffe@gstt.nhs.uk
02071887188
Guy Glover
principal investigator · Guy's and St Thomas' NHS Foundation Trust

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Isoflurane

Start the discussion